Specialty Biotech 13Fs: Sarepta, BioMarin, Alnylam, Ionis Inside

US-traded specialty biotech equities form a distinctive rare disease corner of institutional 13F positioning. Sarepta Therapeutics (SRPT, Duchenne muscular dystrophy plus emerging Elevidys gene therapy), BioMarin Pharmaceutical (BMRN, rare genetic disease plus emerging Voxzogo achondroplasia), Alnylam Pharmaceuticals (ALNY, RNAi platform), Ionis Pharmaceuticals (IONS, antisense oligonucleotide platform), plus Vertex Pharmaceuticals (VRTX, see large biotech decoder), Insmed (INSM, bronchiectasis), and Ultragenyx (RARE) anchor the cohort. Multi-year emerging rare disease economics, gene therapy adoption, plus emerging emerging RNAi plus antisense oligonucleotide platforms drive distinctive institutional positioning.

The specialty biotech business model

Specialty biotech companies operate four primary economic engines:

1. Rare disease economics. Multi-year emerging rare disease economics drives operator economics. Multi-year emerging rare disease (orphan drug FDA designation, fewer than 200K US patients) plus emerging emerging premium pricing ($100K-$3M+ per patient annually) plus emerging emerging emerging emerging market exclusivity plus emerging emerging emerging emerging tax credits plus emerging emerging FDA fast-track plus breakthrough drive operator economics.
2. Gene therapy adoption. Multi-year emerging gene therapy adoption drives multi-year emerging operator strategic positioning. Multi-year emerging Sarepta Elevidys (Duchenne muscular dystrophy AAV gene therapy, FDA approved 2023 plus broadened 2024) plus emerging emerging BioMarin Roctavian (hemophilia A) plus emerging emerging Bluebird Bio plus emerging emerging emerging emerging Casgevy (Vertex-CRISPR Therapeutics, sickle cell gene editing) drive multi-year emerging gene therapy adoption.
3. RNAi platform. Multi-year emerging RNAi (RNA interference) platform drives Alnylam operator economics. Multi-year emerging Alnylam Onpattro plus emerging emerging Amvuttra (TTR amyloidosis) plus emerging emerging Givlaari (acute hepatic porphyria) plus emerging emerging Oxlumo (primary hyperoxaluria) plus emerging emerging Leqvio (PCSK9 cholesterol, Novartis partnered) drive multi-year emerging RNAi revenue. Multi-year emerging emerging ATTR cardiomyopathy expansion plus emerging emerging Helios-B Phase 3 readout.
4. Antisense oligonucleotide platform. Multi-year emerging antisense oligonucleotide (ASO) platform drives Ionis operator economics. Multi-year emerging Ionis Spinraza (Biogen partnered, spinal muscular atrophy) plus emerging emerging Tegsedi plus emerging emerging Waylivra plus emerging emerging Wainua (Astrazeneca partnered TTR amyloidosis) plus emerging emerging Olezarsen (familial chylomicronemia syndrome FDA approved 2024) drive multi-year emerging ASO revenue.

Major US-traded specialty biotech names

Sarepta Therapeutics (SRPT)

Duchenne muscular dystrophy (DMD) focus plus emerging emerging Elevidys gene therapy plus emerging emerging Exondys 51 plus emerging emerging Vyondys 53 plus emerging emerging Amondys 45 plus emerging emerging Doug Ingram CEO leadership.

BioMarin Pharmaceutical (BMRN)

Diversified rare genetic disease plus emerging emerging Voxzogo (achondroplasia children, ages 5+) plus emerging emerging Roctavian (hemophilia A) plus emerging emerging emerging Naglazyme plus emerging emerging Vimizim plus emerging emerging Aldurazyme plus emerging emerging Brimanaden ScrolarA Alexander Hardy CEO leadership.

Alnylam Pharmaceuticals (ALNY)

Dominant RNAi platform plus emerging emerging Amvuttra plus Onpattro (TTR amyloidosis) plus emerging emerging Givlaari plus emerging emerging Oxlumo plus emerging emerging Leqvio (Novartis partnered) plus emerging emerging Yvonne Greenstreet CEO leadership.

Ionis Pharmaceuticals (IONS)

Antisense oligonucleotide (ASO) platform plus emerging emerging Spinraza (Biogen partnered) plus emerging emerging Wainua (Astrazeneca partnered) plus emerging emerging Olezarsen plus emerging emerging Tryngolza (FDA approved 2024) plus emerging emerging Brett Monia CEO leadership.

Insmed (INSM)

Pulmonary rare disease plus emerging emerging Arikayce (nontuberculous mycobacterial lung disease) plus emerging emerging brensocatib (bronchiectasis, FDA target 2025) plus emerging emerging Will Lewis CEO leadership.

Ultragenyx (RARE)

Rare disease plus emerging emerging Crysvita (X-linked hypophosphatemia, KKC partnered) plus emerging emerging Mepsevii plus emerging emerging Dojolvi plus emerging emerging Emil Kakkis founder-CEO leadership.

How institutional managers position around specialty biotech

Three patterns appear across smart-money 13Fs:

Pattern 1: Gene-therapy concentration

SRPT-concentrated growth manager positions reflect Elevidys gene therapy plus emerging emerging emerging DMD franchise thesis.

Pattern 2: RNAi-platform positioning

ALNY-concentrated growth manager positions reflect RNAi platform plus emerging emerging emerging TTR amyloidosis expansion thesis.

Pattern 3: ASO-platform positioning

IONS-concentrated growth manager positions reflect ASO platform plus emerging emerging Wainua plus Olezarsen thesis.

How to read specialty biotech 13F positioning

Three rules apply:

Rule 1: Identify platform exposure

Gene therapy vs RNAi vs ASO vs traditional small molecule have distinct dynamics.

Rule 2: Watch pipeline readouts

Multi-year clinical trial readouts drive operator pipeline.

Rule 3: Cross-check rare disease economics

Multi-year rare disease premium pricing drives operator economics.

What specialty biotech positioning signals

1. Gene-therapy conviction. Concentrated SRPT positions signal Elevidys plus DMD gene therapy thesis.
2. RNAi conviction. Concentrated ALNY positions signal RNAi platform thesis.
3. ASO conviction. Concentrated IONS positions signal ASO platform thesis.

For real-time tracking of specialty biotech 13F activity, see the institutional signals feed.